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ABSTRACT
INCIDENCE OF AND RISK FACTORS FOR ANTHRACYCLINE- AND TRASTUZUMABASSOCIATED CARDIOTOXICITY. Esther Park1, Laura Skrip*1, Christos Hatzis*2, Cary P.
Gross3,4, Maysa Abu-Khalaf2, Raymond Russell5. 1Yale University, School of Medicine, New Haven,
CT; 2Section of Medical Oncology, Department of Internal Medicine, Yale University, School of
Medicine, New Haven, CT; 3Cancer Outcomes, Public Policy and Effectiveness Research Center;
4
Department of Internal Medicine, Yale University, School of Medicine, New Haven, CT; 5Section of
Cardiology; Department of Internal Medicine, Yale University, School of Medicine, New Haven, CT.
*Equal contributors
A major limitation of some of the most effective breast cancer (BC) therapies is the development of
heart failure or left ventricular dysfunction. However, knowledge of the risk factors for development
of cardiotoxicity from use of current standard BC therapies is incomplete. This study aimed to
determine the incidence and predictors of cardiotoxicity associated with anthracycline and
trastuzumab treatment.
We retrospectively identified patients in the Yale Nuclear Cardiology database who were diagnosed
with BC between 2003 and 2013. The patients were grouped into cohorts based on whether they had
received an anthracycline or trastuzumab as a part of their treatment regimen. As some patients had
received both of these agents, the cohorts were not mutually exclusive. The independent variables of
interest were baseline patient characteristics and comorbidities, baseline cardiac imaging parameters,
and treatment factors (radiotherapy, cumulative anthracycline dose, and treatment with other agents).
The endpoint was development of cardiotoxicity, as defined by a new diagnosis of congestive heart
failure (CHF), admission for an acute CHF exacerbation, or a significant pre-defined decline in left
ventricular ejection fraction.
We identified 571 women with BC. In the anthracycline cohort, patients were 50.84 years old on
average (SD: 9.65, n = 496). The 3-year cumulative incidences of cardiotoxicity in the anthracycline
and trastuzumab cohorts were 12.70 and 42.54 cardiac events per 100 people, respectively. The
results of a multivariate Cox proportional-hazards regression analysis suggested that receipt of
bevacizumab or trastuzumab independently increased the risk of cardiotoxicity in patients treated with
an anthracycline (HR: 4.70, 95% CI for HR: 1.78-12.44, p-value: 0.002 or HR: 10.51, 95% CI for HR:
5.83-18.93, p-value: < 0.001, respectively). In the trastuzumab cohort, the mean age was 52.01 (SD:
10.66, n = 134). In a similar multivariate analysis, anthracycline was not shown to increase the
incidence of cardiotoxicity in patients who received trastuzumab, regardless of the cumulative
anthracycline dose level (≤ 240 mg/m2 or > 240 mg/m2). However, dyslipidemia was a significant
risk factor (HR: 3.66, 95% CI for HR: 1.80-7.42, p-value: < 0.001). Interestingly, use of radiotherapy
was associated with a lower incidence of developing cardiotoxicity in the anthracycline and
trastuzumab cohorts, irrespective of the laterality of radiotherapy. A positive smoking history was
related to a shorter time to cardiotoxicity for both the anthracycline and trastuzumab cohorts (HR:
2.82, 95% CI for HR: 1.39-5.71, p-value: 0.0039 and HR: 3.01, 95% CI for HR: 1.42-6.39, p-value:
0.0040, respectively). In the anthracycline cohort, an abnormal baseline left ventricular end-diastolic
volume and an abnormal baseline peak filling rate were not significantly associated with
cardiotoxicity.
In conclusion, trastuzumab and bevacizumab significantly increase risk of cardiotoxicity in patients
who receive an anthracycline. Smoking and dyslipidemia are potential targets for risk reduction. The
lack of a significant cardiotoxic effect associated with radiotherapy suggests that previously accepted
beliefs regarding radiotherapy’s harmful cardiac effects when used for BC treatment may be outdated,
although further analysis in larger groups and accounting for additional confounding variables is
necessary. Future studies are necessary to re-evaluate modern radiotherapy’s cardiac effects.
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INTRODUCTION
Despite improved screening measures and the ability to detect disease at an earlier stage,
breast cancer continues to place a significant burden on public health (1). It accounts for
23% of cancer cases and is the most common cause of cancer-related deaths in women
globally (2). However, scientific advancements continue to expand our understanding of
its pathological characteristics, and we now have a more diverse arsenal of breast cancer
treatments. These include, but are not limited to, chemotherapeutic agents such as
taxanes, anthracyclines, 5-fluorouracil, capecitabine, and cyclophosphamide; endocrine
agents such as aromatase inhibitors and tamoxifen; monoclonal antibodies such as
trastuzumab; antiangiogenic compounds such as bevacizumab; and radiotherapy.
Fortunately, these breast cancer treatments have improved disease-free and overall
survival (3-6). For instance, the NOAH trial found that in patients with HER2-positive
breast cancer who received trastuzumab, the 3-year event-free survival was 71% (3).
This was significantly higher than the 3-year event-free survival of 56% in those who had
not received trastuzumab (3). A pooled analysis also found that higher cumulative
anthracycline doses were significantly associated with pathological complete response
(pCR), particularly in HER2-negative patients (7). The same analysis found other factors
related to chemotherapy, such as an increased number of chemotherapy cycles in
hormone receptor (HR)-positive patients, were significantly associated with pCR as well
(7). Though the BEATRICE trial did not demonstrate improved invasive disease-free
survival with the addition of bevacizumab to adjuvant therapy in those with triplenegative breast cancer (8), the GeparQuinto trial and NSABP B40 trials did demonstrate
significantly increased rates of pCR when bevacizumab was used in the neoadjuvant
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setting (9, 10). While data on whether pCR can be used as a reliable surrogate outcome
marker at the trial-level have been mixed (11-14), pCR may have an individual-level
association with long-term outcome (12, 13). Thus, the positive associations between the
mentioned breast cancer treatments and pCR are encouraging.
The benefits of the currently available breast cancer treatment regimens are significant;
however, one of the major non-malignant complications of these breast cancer therapies
is development of heart failure or ventricular dysfunction (15). While these
developments can be asymptomatic, some are life-threatening and dose-limiting (15).
Anthracycline is one such chemotherapeutic agent used for multiple types of cancer,
including breast cancer (16). Those who receive anthracycline-based therapies for these
various cancers are approximately five times as likely to develop cardiotoxicity than
those who receive non-anthracycline-based therapies (16). Importantly, asymptomatic
cases of cardiotoxicity can progress to irreversible congestive heart failure (CHF) (15).
In addition, the survival associated with doxorubicin-induced cardiomyopathy is worse
than the survival associated with ischemic cardiomyopathy, one of the most common
causes of cardiomyopathy (17).
The putative mechanism behind anthracycline-induced cardiotoxicity continues to be
debated. It had long been believed that anthracycline’s cardiotoxic effects were mediated
by the production of reactive oxygen species (ROS) and increased oxidative stress,
ultimately leading to myofibril loss and myocardial vacuolization (18, 19). However,
several studies assessing the efficacy of anti-ROS agents such as iron chelators have
failed to demonstrate complete protection against doxorubicin-induced cardiotoxicity (19,
20). Rather, the fundamental mechanism of cardiac injury appears to involve the
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topoisomerase-II (Top2) enzyme. Top2α is overexpressed in proliferating cells such as
cancer cells but otherwise is not normally detectable (18).(21) Doxorubicin binds to this
enzyme and DNA, forming a ternary cleavage complex that subsequently activates cell
death (18). However, doxorubicin also binds to Top2β, which is normally expressed in
adult cardiomyocytes (18, 21, 22). The implications of this interaction have been studied
by Zhang et al., who developed a murine model where cardiomyocyte-specific Top2β
was deleted (18). They found that this deletion protected cardiomyocytes not only from
DNA double-stranded breaks and transcriptome changes promoting ROS formation but
also from progressive heart failure following doxorubicin exposure (18).
Trastuzumab is also associated with cardiotoxicity (15). A meta-analysis found that
trastuzumab increased the risk of CHF and declines in left ventricular ejection fraction
(LVEF) by 5.11 and 1.83 times, respectively, when compared to regimens without
trastuzumab (23). The mechanism of trastuzumab-induced cardiotoxicity has not been
completely established, but ErbB2 (HER2/neu) signaling has been implicated. In a
mouse model, ErbB2-deficient mice developed dilated cardiomyopathy and increased
susceptibility to anthracycline-induced cardiotoxicity (24). Other studies in mice also
revealed HER2 signaling to have an important role in proper embryonic cardiac
development (25, 26).
Risk factors for trastuzumab- and anthracycline-induced cardiotoxicity have been studied,
and several have been reported (15, 27, 28). For instance, radiotherapy in patients treated
with high-dose anthracycline regimens has been associated with subsequent development
of cardiotoxicity (29). Higher cumulative anthracycline doses, lengthier durations of
trastuzumab therapy, and concomitant trastuzumab and anthracycline treatment regimens
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have also been associated with development of cardiotoxicity (15). Still, the risk factors
for developing cardiotoxicity have not been completely defined (30). Previous studies
that aimed to identify risk factors may also be outdated, such as those that involved premodern radiotherapy techniques (30). Left-sided radiotherapy can expose the heart to a
greater mean dose of radiation than right-sided radiotherapy due to the heart’s anatomic
position (31), and therefore left-sided radiotherapy may increase a patient’s risk for
developing heart disease. However, this may not be the case in the modern era of
radiotherapy, as the incidental radiation to the heart has now been decreased significantly
(30). Furthermore, there have been few studies on baseline equilibrium radionuclide
angiocardiography (ERNA) imaging parameters as potential predictors of clinically
significant anthracycline- or trastuzumab-induced cardiotoxicity. While baseline left
ventricular ejection fraction is typically evaluated before a patient begins an
anthracycline or trastuzumab, other imaging parameters (such as baseline peak filling rate
and left ventricular end diastolic volume) as potential predictors of cardiotoxicity have
not been as well studied.
These deficiencies are reflected by the lack of detailed guidelines for noninvasive cardiac
monitoring in patients treated with cardiotoxic breast cancer therapies (30). Better
characterization of the risk factors and predictors for cardiotoxicity associated with
modern-day breast cancer therapies is critical for risk-reduction efforts and for
identifying individuals who may need more stringent monitoring of cardiac function.
This would allow earlier detection of cardiotoxicity and subsequent intervention in those
patients who would most benefit from being subjected to more frequent cardiac
evaluations. Early detection of cardiotoxicity is critical since cardioprotective
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interventions implemented at the subclinical stage can be more effective than when
implemented during its later, symptomatic stages (32).

STATEMENT OF PURPOSE AND HYPOTHESES
In this study, we sought to determine the incidence of and risk factors for cardiotoxicity,
as defined by a change in ejection fraction or development of CHF symptoms, associated
with current anthracycline- or trastuzumab-based breast cancer therapies. We also aimed
to evaluate baseline imaging parameters as potential predictors of cardiotoxicity. The
overarching goal was to identify patients who may require risk management and/or more
rigorous cardiac monitoring so that they can continue to benefit from the effective
anthracycline- or trastuzumab-based breast cancer therapies.
Our hypotheses were the following:


Given the development of approaches to reduce cardiotoxicity such as more
targeted radiotherapy techniques (30), the incidence of anthracycline- and
trastuzumab-induced cardiotoxicity is now lower than previously published
incidences.



Increased age, increased BMI, a positive family history of cardiac disease, a
positive smoking history, and renal/cardiovascular/liver comorbidities are
associated with increased risk for developing anthracycline- or trastuzumabinduced cardiotoxicity.



Abnormal left ventricular ejection fraction, peak filling rate, and left ventricular
end-diastolic volume on baseline equilibrium radionuclide angiocardiography are
predictors of cardiotoxicity.
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Left-sided chest radiotherapy is associated with increased risk for developing
anthracycline- or trastuzumab-induced cardiotoxicity.



The risk for developing anthracycline-induced cardiotoxicity increases as the
cumulative dose increases.



Additional treatment (such as trastuzumab, anthracycline, and/or bevacizumab)
increases the risk of developing cardiotoxicity in those who receive trastuzumab
or anthracycline.

METHODS
Data Sources
Data were obtained from the Yale Nuclear Cardiology database, which contains limited
data on patients’ characteristics, comorbidities, and equilibrium radionuclide
angiocardiography (ERNA) findings. The Yale Nuclear Cardiology database was used
for two reasons. Firstly, until approximately two years ago, ERNA was the preferred
method of measuring left ventricular systolic and diastolic function in patients receiving
chemotherapy at Yale. Secondly, the echocardiography reporting system is not
configured to search reliably for patients based on whether they will or have received
chemotherapy.
Medical records from Yale-New Haven Hospital, Hospital of Saint Raphael, Yale
Smilow Cancer Hospital, and Yale Cancer Care Centers were also reviewed to obtain
more complete data about patients’ comorbidities, imaging, and treatment histories. The
Yale University Human Investigation Committee approved this medical record review
(HIC #1303011697). While I performed most of the retrospective chart review, Igor
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Medic, MD; Raymond Russell, MD; and Sara Anwar, MD, also participated during the
initial stages.
Study Sample
Breast cancer patients who received anthracycline (doxorubicin, Doxil, or epirubicin)
and/or trastuzumab as a part of their treatment and whose baseline LVEF was determined
by ERNA were included in the study. Patients were excluded if they met any of the
following criteria: 1) received any chemotherapy or radiotherapy prior to their baseline
ERNA, 2) had a prior diagnosis of a cancer that typically requires chemotherapy or
radiotherapy, or 3) received dexrazoxane during chemotherapy for their breast cancer.
Study Design
This was a retrospective study, where the endpoint and outcome variable was
cardiotoxicity, as indicated by a cardiac event. Data on baseline patient risk factors and
various treatment factors were extracted using a chart abstraction tool that I created for
consistency. Patients were sub-grouped into two cohorts. The anthracycline cohort
consisted of patients who received an anthracycline, regardless of whether or not
trastuzumab was also a part of their treatment regimen. The trastuzumab cohort consisted
of patients who received trastuzumab, regardless of whether or not they received an
anthracycline. These cohorts were therefore not mutually exclusive. However, they
allowed me to identify risk factors specific for developing anthracycline-associated
cardiotoxicity and those specific for developing trastuzumab-associated cardiotoxicity in
our study sample. The length of follow-up was calculated as the time between the start of
chemotherapy, trastuzumab, or bevacizumab and the date of the last clinic/admission note

8

or imaging study (echocardiogram or ERNA). The time to event was calculated as the
time between the start of chemotherapy, trastuzumab, or bevacizumab and the date of a
cardiac event.
Study Variables
Baseline patient characteristics and comorbidities
The following baseline patient risk factors were obtained from the Yale Nuclear
Cardiology database: age, body mass index (BMI), and family history of cardiac disease.
The following baseline patient risk factors were obtained from review of the medical
records: history of dyslipidemia, hypertension, diabetes mellitus, smoking, coronary
artery disease, valvular heart disease, atrial fibrillation, peripheral vascular disease, liver
disease (transient or chronic), stroke or transient ischemic attack, and chronic renal
failure. A patient who was a current smoker or had quit smoking in the past year prior to
the baseline ERNA study was considered to have a positive smoking history.
Baseline imaging parameters
The following baseline imaging parameters were obtained from ERNA results in the Yale
Nuclear Cardiology database: peak filling rate (PFR), left ventricular ejection fraction
(LVEF), and LV end-diastolic volume (EDV). Abnormal values for PFR, LVEF, and LV
EDV are < 2.5 EDV/sec, < 50%, and ≥140 mL respectively.
Treatment factors
Detailed treatment histories were abstracted from the medical records. They included
whether or not the patient received axillary, regional lymph node, and/or chest/breast wall
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radiotherapy for her breast cancer. If such radiotherapy was given, the laterality was
recorded (right only, left only, or both sides). The cumulative anthracycline dose was
also recorded. Epirubicin doses were converted to doxorubicin equivalents according to
the Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of
Childhood, Adolescent, and Young Adult Cancers (Version 3.0) (33).
Additional treatment as a risk factor for cardiotoxicity was also considered. In the
anthracycline cohort, additional treatment was considered to be bevacizumab or
trastuzumab. None of the patients in our study received both bevacizumab and
trastuzumab. The groups in this additional treatment variable were therefore mutually
exclusive and consisted of patients who received (1) no additional treatment, (2)
bevacizumab, or (3) trastuzumab. In the trastuzumab group, additional treatment was
considered to be anthracycline.
Cardiac Event
A cardiac event was defined as or indicated by a new diagnosis of CHF, admission for an
acute CHF exacerbation, or a significant decline in LVEF on subsequent evaluations by
echocardiography or ERNA. A significant decline in LVEF in a patient with a normal
baseline LVEF (≥ 50%) was considered to be a decrease of 10 or more percentage points
from baseline or a decrease to below the institution’s lower limit of normal (50%). A
significant decline in a patient with an abnormal baseline LVEF (< 50%) was considered
to be a decrease of 10 or more percentage points from baseline. When a cardiac event
could be classified as a decline in LVEF or a new diagnosis of CHF, the former
classification was applied.
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Assessment of Left Ventricular Function
Parameters of left ventricular function were quantified by ERNA using serial 5- to 7-min
acquisitions taken from the left anterior oblique view using a nuclear medicine camera
(Myosite, GE Healthcare, Barrington, IL). Red blood cells were labeled in vitro with
925-1,110 MBq of 99mTc-pertechnetate (UltraTag, Mallinckrodt Medical, St. Louis, MO).
LV EDV was ascertained using the Massardo count ratio method (34), and LVEF and
PFR were calculated using previously validated software based on time activity curves
from a region of interest that included the left ventricular cavity (35).
Statistical Analysis
Incidence rates per person-month of follow-up and 3-year cumulative incidences were
calculated for each treatment group. Descriptive statistics were generated as frequencies
for categorical variables and means and standard deviations for continuous variables.
The variables were compared across the treatment groups using the chi-squared test when
counts were above five or Fisher’s exact test when counts were five or below. All
continuous variables were categorized using established cutoff values for
normal/abnormal levels in further analyses. Additionally, within each cohort, the number
of individuals and number of events were considered for each variable category.
Variables with fewer than 5% of the cohort were categorized in any level were excluded
from subsequent univariate and multivariate analyses, except for the radiotherapy
variable. In this case, rather than removing the entire variable, patients who received
bilateral radiotherapy were removed from the multivariate analyses in both cohorts since
this group included too few patients to be considered statistically relevant.
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Unadjusted Kaplan-Meier curves were generated and between-group results were
compared using log rank tests. Cox proportional-hazards models were constructed to
evaluate unadjusted relationships between variables meeting the criteria outlined above
and the outcome. Those variables shown to have statistically significant associations in
the univariate analyses and variables with known clinical significance in relation to
occurrence of cardiotoxicity were included in a multivariate Cox proportional-hazards
regression model.
To evaluate for the interaction of confounding variables when statistical significance
changed between the adjusted and unadjusted analyses, bivariate Cox proportional hazard
models were used. Each potential confounder and the variable significantly associated
with cardiotoxicity in the multivariate analysis only were modeled together to determine
if the adjusted estimate for the effect of the variable was changed relative to the
unadjusted estimate. Statistical analyses were performed by Christos Hatzis, PhD, and
Laura Skrip, MPH, using R Statistical Software version 3.0.1 (Foundation for Statistical
Computing). P-values less than 0.05 were considered statistically significant unless
otherwise indicated.

RESULTS
We identified 571 patients in the Yale Nuclear Cardiology database who were diagnosed
with breast cancer from 2003 through 2013 and met the criteria for inclusion in the
analysis. All patients who qualified for the study were female. Four hundred ninety six
patients received an anthracycline, and 134 patients made up the trastuzumab cohort.
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Within the anthracycline cohort of 496 patients, 389 (78%) received an anthracycline but
no bevacizumab or trastuzumab, 30 (6.0%) received anthracycline + bevacizumab (but no
trastuzumab), and 76 (15%) received anthracycline + trastuzumab (but no bevacizumab)
(Table 1a). Data on additional treatment were missing for one patient receiving an
anthracycline. There were a total of 69 (13.9%) cardiac events in the anthracycline
cohort. All of them were due to significant declines in LVEF. The frequency of
cardiotoxicity did differ across treatment subgroups in the cohort (p < 0.001), with only
6.94% of patients in the anthracycline-only subgroup experiencing an event, but 23.33%
in the anthracycline + bevacizumab subgroup and 46.05% in the anthracycline +
trastuzumab subgroup experiencing cardiotoxicity.
The overall cardiotoxicity incidence rate and 3-year cumulative incidence in the
anthracycline cohort were 0.0032 events/person-month and 12.70 cardiac events per 100
people, respectively (Table 1a). In the anthracycline-only, anthracycline + bevacizumab,
and anthracycline + trastuzumab subgroups, the 3-year cumulative incidences were 5.91,
23.33, and 43.42 cardiac events per 100 people, respectively (p < 0.001).
Patients in the treatment subgroups of the anthracycline cohort did not significantly differ
in terms of proportions of individuals presenting with risk factors, such as history of
dyslipidemia, hypertension, diabetes mellitus, smoking, coronary artery disease, valvular
heart disease, atrial fibrillation, peripheral vascular disease, liver disease (transient or
chronic), stroke or transient ischemia attack, and chronic renal failure (Table 1a).
Furthermore, they did not differ in terms of proportions of individuals with family
histories of cardiac disease. None of the patients in this cohort had valvular heart disease,
and this was not included in Table 1a. The subgroups were likewise similar in terms of

13

age (p = 0.75) and BMI (p = 0.76). Most patients in the anthracycline cohort received
radiotherapy and were similarly likely to have it on the left side only (34.89%) or right
side only (32.66%). This distribution did not significantly vary across treatment
subgroups (p = 0.081). The mean cumulative anthracycline dose received by patients
differed significantly across subgroups (p = 0.013), but there was no significance seen
when the cumulative anthracycline dose was categorized into ≤ 240 mg/m 2 and > 240
mg/m2 (p = 0.11). The mean cumulative anthracycline dose received was 241.3± 24.75
mg/m2 (range: 60 mg/m2-450 mg/m2).
Table 1b provides a descriptive overview of the trastuzumab cohort. Among the 134
patients receiving trastuzumab, 76 (57%) also received an anthracycline, while 57 (43%)
did not receive an anthracycline. Data on additional treatment were missing for one
patient receiving trastuzumab. There were a total of 59 (44.03%) cardiac events in the
trastuzumab cohort. Two (3%) of these events were indicated by a CHF exacerbationrelated hospital admission, while 57 (97%) of them were due to significant declines in
LVEF. The proportion of individuals experiencing a cardiac event was over 40% in both
groups and did not significantly differ between the two groups (p = 0.63). As with the
anthracycline cohort, patients receiving trastuzumab did not significantly differ in terms
of the frequency of most risk factors considered. It was observed, however, that patients
who were on trastuzumab but not an anthracycline were more likely to have a history of
chronic renal failure (10.53% versus 1.33%, p = 0.042). Furthermore, on average,
patients who were on trastuzumab but not an anthracycline were older (55.44 ±11.24
years) than those receiving both trastuzumab and an anthracycline (49.47±9.58 years).
Yet, the groups did not significantly differ in terms of the proportions of individuals over
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65 years old – the age cutoff associated with increased risk of cardiac events. The mean
cumulative anthracycline dose among those who also received an anthracycline was
239.9±19.1 mg/m2 (range: 120 mg/m2-310 mg/m2). None of the patients had valvular
heart disease, and this variable was excluded from the Table 1b.
The overall cardiotoxicity incidence rate and 3-year cumulative incidence in the
trastuzumab cohort were 0.02 events/person-month and 42.54 cardiac events per 100
people, respectively (Table 1b). In the trastuzumab without anthracycline and
trastuzumab with anthracycline subgroups, the 3-year cumulative incidences were 52.27
and 43.42 cardiac events per 100 people, respectively (p = 0.46).
Overall, the median time to event was 10.9 months (range: 1.2-91.0), and the median
follow-up length in those who did not experience a cardiac event was 48.3 months
(range: 0.8-115.6). In the anthracycline cohort, the median time to event was 9.0 months
(range: 1.3-91.0), while the median follow-up length in those who did not experience a
cardiac event was 47.0 months (range: 0.9-115.6). In the trastuzumab cohort, the median
time to event was 9.8 months (range: 1.2-91.0), while the median follow-up length in
those who did not experience a cardiac event was 46.4 months (range: 0.8-99.6).
Select Kaplan-Meier curves for significant univariate relationships between the covariate
and the outcome variable are shown in Figures 1 and 2. In the anthracycline cohort, there
were significant differences in the cardiotoxicity-free survival curves associated with no
additional treatment, bevacizumab as additional treatment, and trastuzumab as additional
treatment (p < 0.001: Figure 1a). Of the three, the group receiving anthracycline and
trastuzumab exhibited the worst cardiotoxicity-free survival curve (Figure 1a).
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Interestingly, in the trastuzumab cohort, anthracycline treatment was not associated with
significantly worse cardiotoxicity-free survival compared to that for patients who did not
receive an anthracycline (p = 0.99: Figure 2a).
In both the anthracycline and trastuzumab cohorts, left-sided and right-sided radiotherapy
were both significantly associated with better cardiotoxicity-free survival compared to no
radiotherapy (anthracycline cohort: p < 0.001 for left-sided versus none, p < 0.001 for
right-sided versus none; trastuzumab cohort: p < 0.001 for left-sided versus none, p =
0.023 for right-sided versus none; Figures 1b and 2b). The laterality of radiotherapy did
not affect cardiotoxicity-free survival in either cohort (anthracycline cohort: p = 0.17 for
left-sided versus right-sided; trastuzumab cohort: p = 0.15 for left-sided versus rightsided; Figures 1b and 2b). A history of dyslipidemia at baseline and age > 65 in those
who received trastuzumab were associated with increased rates of cardiotoxicity
compared to no history of dyslipidemia and age ≤ 65, respectively (p = 0.010 and p <
0.001, respectively).
In the multivariate Cox proportional-hazards regression analysis of the anthracycline
cohort, bevacizumab and trastuzumab significantly increased the risk of cardiotoxicity by
4.70- and 10.51-fold, respectively (HR: 4.70, 95% CI for HR: 1.78-12.44, p-value:
0.0018 and HR: 10.51, 95% CI for HR: 5.83-18.93, p-value: < 0.001, respectively; Table
2). However, both left-sided radiotherapy and right-sided radiotherapy were associated
with a significantly lower risk of cardiotoxicity by 0.16 and 0.30 times, respectively (HR:
0.16, 95% CI for HR: 0.07-0.35, p-value: < 0.001 and HR: 0.30, 95% CI for HR: 0.160.56, p-value: < 0.001, respectively).
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In the multivariate Cox proportional-hazards regression analysis of the trastuzumab
cohort, dyslipidemia was significantly associated with developing cardiotoxicity (HR:
3.66, 95% CI for HR: 1.80-7.42, p-value: < 0.001; Table 3). However, dyslipidemia had
not been a significant risk factor in the anthracycline cohort (Table 2). Again, left-sided
radiotherapy and right-sided radiotherapy were both associated with a significantly lower
risk of cardiotoxicity 0.23 and 0.31 times, respectively (HR: 0.23, 95% CI for HR: 0.100.52, p-value: < 0.001 and HR: 0.31, 95% CI for HR: 0.15-0.64, p-value: 0.0017,
respectively). Although age was a significant risk factor in the unadjusted analysis, it
was no longer a significant risk factor after adjusting for the other covariates. Also, as
seen in the Kaplan-Meier curves, anthracycline treatment at either of the cumulative dose
levels (≤ 240 mg/m2 or > 240 mg/m2) did not significantly add to the risk of developing
cardiotoxicity.
In both cohorts, smoking history was not a significant risk factor in the univariate
analysis (Tables 2 and 3). However, it was a significant risk factor for developing
cardiotoxicity after adjustment in the multivariate Cox proportional-hazards regression
analysis (Tables 2 and 3). In the anthracycline cohort, the adjusted hazard ratio was 2.82
(95% CI for HR: 1.39-5.71, p-value: 0.0039). In the trastuzumab cohort, the adjusted
hazard ratio was 3.01 (95% CI for HR: 1.42-6.39, p-value: 0.0040). In the anthracycline
cohort, the smoking effect had been confounded by radiotherapy, which is associated
with a lower risk of developing cardiotoxicity in our study. In the trastuzumab cohort,
dyslipidemia and age were found to be confounders.
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A history of HTN, diabetes mellitus, and liver disease were not significant predictors of
developing cardiotoxicity in either cohort (Tables 2 and 3). Body mass index and a
family history of cardiac disease were also not significant risk factors.
Baseline imaging factors were evaluated in the anthracycline cohort. For the sample of
breast cancer patients receiving an anthracycline, the median LV EF was 63.0% (range:
44.0 – 79.0), median PFR was 3.21 EDV/sec (range: 1.22 – 5.54), and median LV EDV
was 101.0 mL (range: 46.0 – 253.0). Abnormal baseline LV EF values were only
observed in approximately 1% of the sample, while abnormal PFR and LV EDV levels
were found in almost 14% and 16.5% of the sample, respectively. The treatment
subgroups did not differ significantly in their relative proportions of individuals with
abnormal imaging factor levels (Table 4).
Kaplan-Meier curves for univariate relationships between the baseline imaging factors
and the outcome variable in the anthracycline cohort were also generated and compared.
An enlarged left ventricular cavity on the baseline study (LV EDV ≥140 mL) was
associated with a significantly reduced cardiotoxicity-free survival compared to a normal
LV EDV less than 140 mL (p-value = 0.030: Figure 3a). However, an abnormal PFR,
indicating the presence of abnormal left ventricular relaxation, was not associated with a
significantly different cardiotoxicity-free survival curve compared to a normal PFR (p =
0.51: Figure 3b). None of the five individuals with an abnormal LVEF developed
cardiotoxicity, but there were not enough individuals with an abnormal LVEF to include
in the univariate analyses.
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In the univariate Cox proportional-hazards analysis, an abnormal PFR again was not
significantly associated with cardiotoxicity in the anthracycline cohort. However, those
with an abnormal LV EDV had a significantly faster time to event than those with a
normal LV EDV (HR: 1.80, 95% CI for HR: 1.05-3.08, p-value 0.032; Table 5). After
adjusting for cumulative anthracycline dose, additional treatment, chest radiotherapy,
age, BMI, smoking history, family history of cardiac disease, and comorbidities
(hypertension, diabetes, dyslipidemia, and liver disease) in a multivariate Cox
proportional-hazards model, neither PFR nor LV EDV was significantly associated with
cardiotoxicity (Table 5).
It should be noted that a univariate Cox proportional-hazards analysis was carried out for
the trastuzumab cohort as well. However, neither PFR nor LV EDV was significantly
associated with the development of cardiotoxicity, and therefore a multivariate analysis
was not pursued. Furthermore, there were not enough individuals with an abnormal
LVEF from the trastuzumab cohort to include in the Cox proportional-hazards analyses.

DISCUSSION
Several important findings have resulted from the described investigations. Some of the
results confirm the conclusions of prior studies, while others challenge previously
accepted beliefs. The most unexpected of the latter were those of radiotherapy’s
association with decreased rates of cardiotoxicity.
Radiotherapy for breast cancer has been known to be potentially cardiotoxic, as
supported by large meta-analyses of randomized trials (36, 37). Both Cuzick et al. and
the Early Breast Cancer Trialists’ Collaborative Group found that radiotherapy increased
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cardiac or vascular mortality, respectively, when compared to breast cancer patients who
didn’t receive radiotherapy (36, 37). However, most of the trials included in these metaanalyses utilized pre-modern radiotherapy techniques, which delivered greater amounts
of radiation to the heart (30, 36, 37). Since around 1985, more modern techniques such
as image-guided therapy, reduction of field size, and respiratory gating have been used to
reduce incidental cardiac irradiation (30).
Tumor registry studies have demonstrated the impact of these changes in radiotherapy
techniques over time (31, 38). Giordano et al. examined three time periods during which
patients were diagnosed with breast cancer: 1973-1979, 1980-1984, and 1985-1989 (31).
During the first time period, they found that those who received left-sided radiotherapy
had a 15-year mortality from ischemic heart disease of 13.1%, which was significantly
different from the 10.2% 15-year mortality of those who received right-sided
radiotherapy (31). However, in the two latter time periods, no mortality differences were
observed based on laterality of radiotherapy (31). Furthermore, 15-year mortality
decreased from 13.1% to 5.8% over the three time periods in those who received leftsided radiotherapy. These findings were presumably due at least in part to changing
radiotherapy techniques that delivered less radiation to the heart (31). Left-sided
radiotherapy exposes the heart to a greater mean dose of radiation than right-sided
radiotherapy due to the heart’s anatomic position (31). However, Giordano’s findings
suggest that with changing radiotherapy techniques over time, radiation exposure from
left-sided radiotherapy has decreased such that it no longer confers a significantly higher
risk of mortality from ischemic heart disease than right-sided radiotherapy. Darby et al.
had similar findings, with patients who received left-sided radiation between 1973 and
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1982 experiencing significantly higher cardiac mortality rates than those who received
right-sided radiation (38). These differences were no longer significant in later time
periods (38).
Findings from other recent studies on breast cancer patients have been conflicting. Hojris
et al. performed an analysis of two randomized trials and found that radiotherapy did not
increase the risk of ischemic heart disease, including myocardial infarction (39). Doyle
et al. focused their study on women ≥65 years of age and found that the risk of
myocardial infarction likewise did not increase with receipt of radiotherapy, regardless of
tumor laterality (40). On the other hand, McGale et al. demonstrated in a prospective
study that left-sided radiotherapy increases the risk for heart disease, relative to rightsided radiotherapy, even for women diagnosed with breast cancer after 1990, a time
during which they would have presumably been treated with more modern radiotherapy
techniques (41). According to Darby et al., even low doses of radiotherapy are associated
with increased risk for ischemic heart disease (42).
It should be mentioned, though, that these studies are not comparable to ours. Unlike our
study, the outcome of interest in many of these analyses was cardiac ischemia, which is
presumably due to the mechanism of radiotherapy-induced cardiotoxicity. Radiotherapy
is known to induce atherosclerosis, particularly at higher doses (43). Still, radiotherapy
can also damage the microvasculature and promote inflammatory changes and interstitial
fibrosis, potentially resulting in congestive heart failure (43).
There have been studies that explored the effects of radiotherapy on subsequent
development of heart failure or decreases in LVEF in breast cancer patients, though these
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are not as frequent as those on cardiac ischemia (44-48). Some have found that
radiotherapy does not increase the risk of developing these cardiac outcomes (44, 46, 48),
while others have found that they do increase the risk (45, 47). However, these studies
differed from ours in that not all of the patients received chemotherapy (44), patients
were treated with radiotherapy in an earlier time period (1970-1986) (45), or the patients
received trastuzumab and radiotherapy concurrently (46-48). At our institution,
trastuzumab is typically held during courses of radiotherapy.
Our study is unique in that modern radiotherapy, regardless of laterality, was associated
with significant improved cardiac outcomes in breast cancer patients who received an
anthracycline and/or trastuzumab. Reports of radiotherapy having a cardioprotective
effect in breast cancer patients are rare. We have only encountered one such report (49),
and even then, it was not presented as one of the main results. Specifically, Du et al.
found that patients ≥ 65 years of age who receive radiotherapy are less likely to develop
congestive heart failure than those who do not (49).
Despite the lack of pre-existing evidence, the idea that radiotherapy can be
cardioprotective is not entirely far-fetched. Experiments have demonstrated that low
doses of <1 Gy can have anti-inflammatory effects (50, 51). In hypercholesterolemic
mice, exposure to low doses of radiation is associated with reductions in the numbers and
sizes of atherosclerotic lesions and in total serum cholesterol levels (52). It is possible
that the cardioprotective effect seen in our study was possibly due to a preconditioning
effect, akin to ischemic preconditioning where brief periods of ischemia can protect
against more prolonged insults (53). Low doses of radiation to the heart may have
protected it against further insults from chemotherapy and/or trastuzumab.
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Still, the cardioprotective effects seen in our study should be considered with caution, as
there may be potential confounding with factors such as additional treatment type. In the
anthracycline cohort (excluding those who got bilateral radiotherapy since they had also
been excluded from the multivariate analyses), 20 (27%) of the 74 patients treated with
trastuzumab received left-sided radiotherapy. However, 152 (38%) of the 400 patients
who weren’t treated with trastuzumab received left-sided radiotherapy. This bias almost
reaches significance (Fisher’s exact test p-value = 0.09). Given that trastuzumab (as will
be further discussed later) exhibited a very significant cardiotoxic effect in our study, this
potential confounding finding could thus have produced the cardioprotective effect.
However, this reasoning fails when applied to right-sided radiotherapy. In the same
anthracycline cohort (again excluding those who received bilateral radiotherapy), 24
(32%) of the 74 patients treated with trastuzumab underwent right-sided radiotherapy.
Similarly, 136 (34%) of the 400 patients who were not treated with trastuzumab were
given right-sided radiotherapy (Fisher’s exact test p-value = 0.89). There is no clear bias
in this case that could explain the significant cardioprotective effect exhibited by rightsided radiotherapy.
Furthermore, the trastuzumab cohort does not lend itself to a similar evaluation of
potential confounding with additional treatment type since all of the patients had received
trastuzumab. As will be discussed later, additional anthracycline treatment is not
associated with increased risk of cardiotoxicity in this cohort. Therefore, any differences
in the proportions of patients given radiotherapy who did or did not receive anthracycline
treatment in addition to trastuzumab is not of relevance in this particular discussion.

23

Though the observed beneficial effects cannot be completely attributed to confounding
by additional treatment, the bias seen in the anthracycline cohort is a reminder of the
limitations of a retrospective study. There may be several other confounding factors that
we were unable to adjust for in this study. As such, it would be premature to definitely
conclude that radiotherapy is cardioprotective based on our findings. Rather, until our
findings can be reproduced by other studies and trials, emphasis should be placed instead
on the lack of a significant cardiotoxic effect associated with radiotherapy. The absence
of this relationship in our results suggests that previously accepted beliefs regarding
radiotherapy’s harmful cardiac effects may be outdated. There is a need for newer
studies determining the effects of modern radiotherapy on the heart in the setting of
contemporary breast cancer treatments.
As discussed above, another finding of our study is that certain treatment agents add to
cardiotoxicity risk. It has been well established that trastuzumab increases the risk of
developing cardiotoxicity when given to patients who also receive anthracycline, as we
confirmed in our study (48, 49, 54, 55). However, anthracycline at either cumulative
dose levels (≤240 mg/m2 or >240 mg/m2) did not add to the risk of developing
cardiotoxicity in the trastuzumab cohort, when compared to the no-anthracycline
subgroup. This is contrary to previous findings of increased risk with treatments based
on both anthracycline and trastuzumab (56), and we suspect that the negative finding was
perhaps partly due to a treatment bias. Patients who were not given both trastuzumab and
anthracycline may have had a greater predisposition for developing cardiotoxicity than
those who did receive both. There may have been aspects of their medical history that
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discouraged clinicians from treating patients who had to receive trastuzumab in addition
to an anthracycline.
Similarly, the 3-year cumulative incidence of cardiac events was higher in the
anthracycline plus trastuzumab subgroup of the anthracycline cohort than in the
anthracycline-only subgroup (43.42 cardiac events per 100 people versus 5.91 cardiac
events per 100 people). However, in the trastuzumab cohort, there was no significant
difference between the trastuzumab without anthracycline (52.27 cardiac events per 100
people) and trastuzumab plus anthracycline subgroups (43.42 cardiac events per 100
people) (p = 0.46).
The incidences observed in our study are generally higher than those published in other
studies. For example, the observed 3-year cumulative incidences of heart failure or
cardiomyopathy in a retrospective study of elderly women were 28.2, 15.3, and 26.7 per
100 patients in its anthracycline plus trastuzumab, anthracycline (without trastuzumab),
and trastuzumab (without anthracycline) groups, respectively (54). The Herceptin
Adjuvant (HERA) trial found the incidence of left ventricular dysfunction at 3.6 years of
follow-up to be just 9.8% in those who received trastuzumab (57). The North Central
Center Treatment Group (NCCTG) N9831 trial observed even lower cumulative
incidences of 0.3% in the anthracycline (without trastuzumab) group and 2.8% in the
sequential anthracycline plus trastuzumab (plus paclitaxel) group at 3 years (58).
Similarly, the 5-year cumulative incidence in the National Surgical Adjuvant Breast and
Bowel Project (NSABP) B-31 trial was 0.9% in the anthracycline (without trastuzumab)
group and 3.8% in the sequential anthracycline plus trastuzumab/paclitaxel group (58).
The Breast Cancer International Research Group 006 trial likewise observed lower
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incidences of cardiotoxicity despite having a longer mean length of follow-up (56).
However, unlike our study, these studies did not include subclinical cardiotoxicity in their
definition of a cardiac endpoint (54) or excluded those with cardiovascular disease (5759). We suspect that our findings are closer to the true incidence of cardiotoxicity in
anthracycline and/or trastuzumab-treated breast cancer patients.
Bevacizumab was another therapeutic agent that significantly increased the risk of
developing cardiotoxicity in the anthracycline cohort. The data regarding this agent’s
cardiac effects are mixed, with some studies finding that it increases the risk for
congestive heart failure (60, 61), while others reporting that it does not (62). It will be
important to study further bevacizumab’s cardiac toxicities as it has been an agent of
interest due to findings that it increases the pathologic complete response rate and
improves progression-free survival (63, 64).
Additionally, we found that dyslipidemia was a significant risk factor of cardiotoxicity in
the trastuzumab cohort. A positive smoking history was a significant predictor in both
the trastuzumab and anthracycline cohorts. Previous studies, including the NSABP B-31
and HERA trials, did not find them to be significant risk factors for the development of
CHF (48, 65, 66). However, smoking was a positive predictor for trastuzumab mediated
cardiotoxicity in a retrospective study (67). A speckle tracking echocardiographic study
also found that smoking negatively affected longitudinal strain in breast cancer patients
who received chemotherapy (68). It is suspected that smoking may contribute to
cardiotoxicity by increasing oxidative stress (68). In the majority of these previous
studies, it is unclear what was considered to be a positive smoking history. In our study,
current smokers and those who had quit within the year prior to their baseline ERNA
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were considered to have a positive smoking history. Patients who had quit smoking more
than a year prior to their baseline ERNA were considered to have a negative smoking
history. As such, our findings suggest that recent or current smoking is a potential target
for risk reduction and lifestyle modification, as well as dyslipidemia.
A cumulative anthracycline dose > 240 mg/m2 (240 mg/m2 is the cumulative dose
typically used to treat breast cancer) was a negative predictor for cardiotoxicity.
However, it has been well established that higher doses, particularly those greater than
550 mg/m2, are associated with increased risk (15). Our finding is likely due to the study
not being sufficiently powered to detect a difference between the two levels. Only a
small proportion of patients had received cumulative anthracycline doses > 240 mg/m2
(7.28% in the anthracycline cohort and 7.04% of those who received anthracycline in the
trastuzumab cohort: Tables 1a and 1b). Furthermore, the highest cumulative
anthracycline dose in the anthracycline cohort was just 450 mg/m2, while the highest
cumulative anthracycline dose in the trastuzumab cohort was 310 mg/m2.
An abnormal baseline LV EDV was significantly associated with cardiotoxicity in the
univariate Cox proportional-hazards analysis of the anthracycline cohort. However, after
adjustment for various patient and treatment-related factors, the association was no longer
significant. An abnormal baseline PFR, a marker of diastolic dysfunction, was not
significantly associated with cardiotoxicity in either the univariate or multivariate
analysis. Unfortunately, there are no other studies on abnormal baseline ERNA imaging
factors that predict cardiotoxicity. However, there have been studies that have assessed
various imaging parameters obtained during cancer treatment or post-treatment as
subclinical predictors of subsequent significant changes in LVEF or heart failure (in
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contrast to assessing pre-treatment ERNA imaging parameters as predictors of
developing cardiotoxicity such as in our study). Though the questions addressed by these
studies and ours are fundamentally different, we can use the findings of the former as a
starting point for discussion.
There have been studies that have focused on early diastolic abnormalities as potential
predictors of cardiotoxicity. A case series of three patients who received doxorubicin
found that a decrease in the PFR preceded development of changes in LVEF and the
development of CHF (69). The authors therefore proposed PFR as a more sensitive
marker of early cardiotoxicity than the conventional marker, LVEF (69). Hashimoto et
al. also found that the PFR was significantly lower in pediatric patients who received
anthracycline compared to a control group, even though there was no significant
difference in LVEF between the two groups (70). However, they did not determine
whether this potential marker of subclinical cardiotoxicity could be used as a predictor of
subsequent changes in LVEF or CHF (70).
The aforementioned studies suggest that chemotherapy-induced cardiotoxicity may be a
step-wise process whereby the myocardium undergoes several phases of injury, with
diastolic changes perhaps preceding systolic changes. If so, it would seem sensible that
patients with baseline abnormalities in PFR or LV EDV prior to beginning anthracyclineor trastuzumab-based treatment would be predisposed to developing cardiotoxicity (as
defined by significant declines LVEF or CHF manifestations) due to pre-existing
diastolic abnormalities. However, this hypothesis did not hold up in our study. This may
be at least partly explained by some important differences between previous studies and
ours. Namely, the cancer types being treated in previous studies were varied and
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included diagnoses such as rhabdomyosarcoma, acute lymphoblastic leukemia, Wilm’s
tumor, breast carcinoma, and small cell lung carcinoma (69, 70). Therefore, the
cumulative doses of anthracycline that patients received in the case series (69) (mean:
385 ± 105 mg/m2) and the study by Hashimoto et al. (70) (mean: 305 ± 236 mg/m2) were
on average higher than the cumulative anthracycline doses that our patients received
(mean: 241.3 ± 24.75 mg/m2). It may be that the typical cumulative anthracycline doses
administered during the treatment of breast cancer, such as in our study sample, are not
high enough to cause significant enough additional diastolic damage. Regardless, our
findings suggest that a PFR < 2.5 EDV/sec and an LV EDV ≥140 mL are not strong
predictors of cardiotoxicity in breast cancer patients who receive anthracycline- and/or
trastuzumab-based treatments.
It would be reasonable to expect an abnormal baseline LVEF to be a predictor of
cardiotoxicity, particularly since the definition of cardiotoxicity in our study includes
significant declines in LVEF. However, a limitation of our study was that there were
only a few patients with an abnormal baseline LVEF, and meaningful statistical analyses
of their potential implications could not be carried out. Based on a recent systematic
review, an early 10%-15% reduction in peak systolic global longitudinal strain (GLS), as
determined by speckle tracking echocardiography (STE), seems to be a valuable predictor
of subsequent LVEF declines or heart failure in patients who received trastuzumab and/or
anthracycline (32). Such findings highlight the importance of studying baseline LVEF
as a potential predictor of cardiotoxicity in future studies that are sufficiently powered to
do so.
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Future studies should also focus on further examination of the effects of radiotherapy,
bevacizumab, dyslipidemia, and smoking on risk of developing cardiotoxicity in breast
cancer patients. They are potentially important for risk stratification and reduction. In
particular, our findings on radiotherapy illustrate that its effects are not simply
cardiotoxic, but that it has a complicated relationship with other treatment factors. It
seems that modern radiotherapy techniques that deliver low doses of radiation to the
heart, when given after relatively low cumulative doses of anthracycline typical of
standard breast cancer chemotherapy, can be potentially cardioprotective against left
ventricular systolic dysfunction and heart failure. However, we can only be speculative
at this point given the potential for confounding factors and instead place more
confidence on the lack of a significant cardiotoxic effect associated with radiotherapy.
More studies are necessary to assess the validity of our results and further explore the
relationship between low doses of radiotherapy and development of congestive heart
failure or systolic dysfunction in breast cancer patients. Future investigations should
stratify radiotherapy not just by laterality but also by region and total dose of radiation to
the heart. It will also be important to determine whether or not the potential
cardioprotective effects of radiotherapy seen in our study, if reproducible, are long-term
and persist beyond the follow-up duration of our study. In addition, it will be important
to see if there is a linear relationship between cigarette pack-years and risk of developing
cardiotoxicity and if there is a minimum pack-year level beyond which risk begins to
increase. Elucidating the effects of statin therapy and disease control on dyslipidemia’s
contributions to cardiotoxicity will also be important.
Study limitations

30

The greatest limitation of our study was that it was retrospective. However, we attempted
to minimize confounding factors and bias by adjusting for many potential confounders
and appropriately limiting our sample. Patients who had previously received
chemotherapy and/or radiotherapy or were diagnosed with a cancer that would have
required either were excluded. Secondly, the study relied on the identification of a cohort
of patients based on determination of the baseline LVEF by ERNA. Therefore, patients
whose baseline LVEF was determined by echocardiogram were not included. However,
based on referral patterns at our institution, we have no reason to believe that there would
be significant baseline differences between those who underwent an ERNA versus an
echocardiogram. As mentioned previously, the small sample size of patients with an
abnormal baseline LVEF was another limitation that prevented meaningful statistical
analysis of its association with developing cardiotoxicity.
Conclusions
In both the anthracycline and trastuzumab cohorts of breast cancer patients, radiotherapy
was associated with a lower risk of a subsequent decrease in LVEF or development of
CHF. However, there may have been confounding factors that this study could not adjust
for, and emphasis should instead be placed on the lack of a significant cardiotoxic effect
associated with radiotherapy. Dyslipidemia and a positive smoking history are
significant predictors for the development of cardiac events and potential targets for risk
reduction. Trastuzumab and bevacizumab independently increased the risk of
cardiotoxicity in patients who received an anthracycline. Abnormal baseline LV EDV
and PFR do not appear to be strong predictors of anthracycline- or trastuzumab-induced
cardiotoxicity. Patients with the aforementioned significant risk factors may benefit from
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more stringent cardiac monitoring for earlier detection of subclinical myocardial injury so
that the benefits of receiving effective breast cancer treatments such as anthracyclines or
trastuzumab will outweigh the costs of cardiotoxicity. Future studies are necessary to
establish such benefits and determine the optimal monitoring parameters and frequency.
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FIGURES
Figure 1a. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the
Anthracycline Cohort Based on Additional Treatment

Figure 1b. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the
Anthracycline Cohort Based on Radiotherapy Location
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Figure 2a. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the
Trastuzumab Cohort Based on Additional Treatment

Figure 2b. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the
Trastuzumab Cohort Based on Radiotherapy Location
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Figure 3a. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the
Anthracycline Group Based on Left Ventricular End-Diastolic Volume (LV EDV)

Figure 3b. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the
Anthracycline Group Based on Peak Filling Rate (PFR)

TABLES
Table 1a. Descriptive Summary of the Anthracycline Cohort
All Breast Cancer
Patients Receiving
Anthracycline
Characteristic
n = 496
0.0032
Incidence Rate (events/person-month)
3-Year Cumulative Incidence (per 100
12.70
people)
Cardiotoxic Event
Event
69 (13.9)
No Event
427 (86.1)
Cumulative Anthracycline Dose
(mg/m2)
Mean ± SD
241.3 ± 24.75
≤ 240
420 (92.72)
> 240
33 (7.28)
Radiotherapy
Left-sided only
172 (34.89)
Right-sided only
161 (32.66)
Both left- and right-sided
18 (3.65)
None
142 (28.80)
Age (years)
Mean ± SD
50.84 ± 9.65
≤ 65
462 (93.15)
> 65
34 (6.85)

Anthracycline
- Bevacizumab
- Trastuzumab
n = 389
0.0015

Anthracycline
+
Bevacizumab
n = 30
0.0068

Anthracycline
+
Trastuzumab
n = 76
0.014

<0.001*

5.91

23.33

43.42

<0.001*

27 (6.94)
362 (93.06)

7 (23.33)
23 (76.67)

35 (46.05)
41 (53.95)

<0.001*

240.5 ± 23.08
330 (93.48)
23 (6.52)

254.4 ± 45.76
24 (82.76)
5 (17.24)

239.9 ± 19.11
66 (92.96)
5 (7.04)

0.013*
0.11

140 (36.18)
126 (32.56)
14 (3.62)
107 (27.65)

12 (40.00)
10 (33.33)
3 (10.00)
5 (16.67)

20 (26.67)
24 (32.00)
1 (1.33)
30 (40.00)

0.081

51.27 ± 9.59
360 (92.54)
29 (7.46)

48.53 ± 10.29
29 (96.67)
1 (3.33)

49.47 ± 9.58
72 (94.74)
4 (5.26)

0.13
0.75

p-value
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Table 1a continued
BMI
Mean ± SD
Normal
Overweight
Obese
Hypertension
Yes
No
Diabetes Mellitus
Yes
No
Dyslipidemia
Yes
No
History of Smoking
Yes
No
Family History of Cardiac Disease
Yes
No
Coronary Artery Disease
Yes
No

27.97 ± 6.88
183 (37.97)
156 (32.37)
143 (29.67)

28.14 ± 7.00
144 (37.70)
123 (32.20)
115 (30.10)

27.54 ± 5.47
9 (31.03)
12 (41.38)
8 (27.59)

27.06 ± 6.67
30 (42.86)
21 (30.00)
19 (27.14)

0.45
0.76

149 (30.41)
341 (69.59)

123 (31.95)
262 (68.05)

9 (30.00)
21 (70.00)

17 (22.67)
58 (77.33)

0.28

44 (8.96)
447 (91.04)

36 (9.33)
350 (90.67)

1 (3.33)
29 (96.67)

7 (9.33)
68 (90.67)

0.69

114 (23.27)
376 (76.73)

91 (23.64)
294 (76.36)

5 (16.67)
25 (83.33)

18 (24.00)
57 (76.00)

0.68

80 (16.33)
410 (83.67)

61 (15.89)
323 (84.11)

6 (20.00)
24 (80.00)

13 (17.33)
62 (82.67)

0.74

230 (46.75)
262 (53.25)

185 (47.80)
202 (52.20)

12 (40.00)
18 (60.00)

32 (43.24)
42 (56.76)

0.58

5 (1.02)
485 (98.98)

4 (1.04)
381 (98.96)

0 (0.00)
30 (100.00)

1 (1.33)
74 (98.67)

0.70
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Table 1a continued
Atrial fibrillation
Yes
1 (0.20)
1 (0.26)
0 (0.00)
0 (0.00)
No
489 (99.80)
384 (99.74)
30 (100.00)
75 (100.00)
No
489 (99.80)
385 (100.00)
30 (100.00)
74 (98.67)
Liver Disease
Chronic
2 (0.41)
2 (0.52)
0 (0.00)
0 (0.00)
Transient
43 (8.78)
34 (8.83)
3 (10.00)
6 (8.00)
None
445 (90.82)
349 (90.65)
27 (90.00)
69 (92.00)
Stroke/TIA
Yes
6 (1.22)
4 (1.04)
0 (0.00)
2 (2.67)
No
485 (98.78)
382 (98.96)
30 (100.00)
73 (97.33)
Chronic renal failure
Yes
5 (1.02)
4 (1.04)
0 (0.00)
1 (1.33)
No
485 (98.98)
381 (98.96)
30 (100.00)
74 (98.67)
Note: Data are n (%) of persons for whom data are available. Percentages may not sum to one hundred due to rounding.
* Statistically significant at the p < 0.05 level
BMI = body mass index; TIA = transient ischemic attack; SD = standard deviation

1.0

0.95

0.49

0.70
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Table 1b. Descriptive Summary of the Trastuzumab Cohort

n = 134

Trastuzumab
without
Anthracycline
n = 57

Trastuzumab
with
Anthracycline
n = 76

0.015

0.017

0.014

0.46

42.54

52.27

43.42

0.46

59 (44.03)
75 (55.97)

23 (40.35)
34 (59.65)

35 (46.05)
41 (53.95)

0.63

38 (28.79)
35 (26.52)
2 (1.52)
57 (43.18)

18 (31.58)
11 (19.30)
1 (1.75)
27 (47.37)

20 (26.67)
24 (32.00)
1 (1.33)
30 (40.00)

0.42

52.01 ± 10.66
122 (91.04)
12 (8.96)

55.44 ± 11.24
49 (85.96)
8 (14.04)

49.47 ± 9.58
72 (94.74)
4 (5.26)

0.0017*
0.12

26.92 ± 6.28
55 (42.97)
42 (32.81)
31 (24.22)

26.69 ± 5.86
25 (43.86)
21 (36.84)
11 (19.30)

27.06 ± 6.67
30 (42.86)
21 (30.00)
9 (27.14)

0.74
0.75

All Breast Cancer Patients
Receiving Trastuzumab
Characteristic
Incidence Rate (events/personmonth)
3-Year Cumulative Incidence (per
100 people)
Cardiotoxic Event
Event
No Event
Radiotherapy
Left-sided only
Right-sided only
Both left- and right-sided
None
Age (years)
Mean ± SD
≤ 65
> 65
BMI
Mean ± SD
Normal
Overweight
Obese

p-value
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Table 1b continued
Hypertension
Yes
No
Diabetes Mellitus
Yes
No
Dyslipidemia
Yes
No
History of Smoking
Yes
No
Family History of Cardiac Disease
Yes
No
Coronary Artery Disease
Yes
No
Atrial fibrillation
Yes
No
Peripheral vascular disease
Yes
No

38 (28.57)
95 (71.43)

21 (36.84)
36 (63.16)

17 (22.67)
58 (77.33)

0.11

10 (7.52)
123 (92.48)

3 (5.26)
54 (94.74)

7 (9.33)
68 (90.67)

0.51

33 (24.81)
100 (75.19)

15 (26.32)
42 (73.68)

18 (24.00)
57 (76.00)

0.92

24 (18.05)
109 (81.95)

11 (19.30)
46 (80.70)

13 (17.33)
62 (82.67)

0.95

61 (47.67)
67 (52.34)

29 (54.72)
24 (45.28)

32 (43.24)
42 (56.76)

0.27

2 (1.50)
131 (98.50)

1 (1.75)
56 (98.25)

1 (1.33)
74 (98.67)

1.0

1 (0.75)
132 (99.25)

1 (1.75)
56 (98.25)

0 (0.00)
75 (100.00)

0.43

1 (0.75)
132 (99.25)

0 (0.00)
57 (100.00)

1 (1.33)
74 (98.67)

1.0
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Table 1b continued
Liver Disease
Chronic
1 (0.75)
1 (1.75)
0 (0.00)
Transient
8 (6.02)
2 (3.51)
6 (8.00)
None
124 (93.23)
54 (94.74)
69 (92.00)
Stroke/TIA
Yes
3 (2.26)
1 (1.75)
2 (2.67)
No
130 (97.74)
56 (98.25)
73 (97.33)
Chronic renal failure
Yes
7 (5.26)
6 (10.53)
1 (1.33)
No
126 (94.74)
51 (89.47)
74 (98.67)
Note: Data are n (%) of persons for whom data are available. Percentages may not sum to one hundred due to rounding.
* Statistically significant at the p < 0.05 level
BMI = body mass index; TIA = transient ischemic attack; SD = standard deviation

0.28

1.0

0.042*
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Table 2. Univariate and Multivariate Cox Proportional-Hazards Regression Analysis of the Anthracycline Cohort
Characteristics
Anthracycline Dose
≤ 240 mg/m2
> 240 mg/m2
Additional Treatment
None
Bevacizumab
Trastuzumab
Radiotherapy
None
Left-Sided Only
Right-Sided Only
Age
≤ 65
> 65
BMI
Normal
Overweight
Obese
Hypertension
Diabetes
Dyslipidemia
Smoking History
Family History of Cardiac
Disease
Liver Disease

Unadjusted HR

(95% CI)

p-value

Adjusted HR

(95% CI)

p-value

Reference
1.68

--(0.76, 3.68)

0.17

Reference
1.72

--(0.70, 4.19)

0.24

Reference
3.56
7.96

--(1.55, 8.20)
(4.81, 13.18)

0.0028*
<0.001*

Reference
4.70
10.51

--(1.78, 12.44)
(5.83, 18.93)

0.0018*
<0.001*

Reference
0.19
0.32

--(0.10, 0.37)
(0.18, 0.56)

<0.001*
<0.001*

Reference
0.16
0.30

--(0.07, 0.35)
(0.16, 0.56)

<0.001*
<0.001*

Reference
1.71

--(0.78, 3.75)

0.18

Reference
1.67

--(0.58, 4.83)

0.34

Reference
0.93
0.77
0.64
0.79
1.18
1.42
0.96

--(0.53, 1.62)
(0.42, 1.41)
(0.36, 1.14)
(0.32, 1.97)
(0.69, 2.02)
(0.79, 2.56)
(0.60, 1.54)

0.79
0.39
0.13
0.62
0.55
0.24
0.87

Reference
0.77
0.96
0.85
0.58
1.69
2.82
1.13

--(0.40, 1.48)
(0.44, 2.08)
(0.39, 1.86)
(0.19, 1.78)
(0.87, 3.32)
(1.39, 5.71)
(0.65, 1.98)

0.43
0.91
0.68
0.34
0.12
0.0039*
0.66

0.98

(0.42, 2.26)

0.95

1.01

(0.36, 2.83)

0.98

* Statistically significant at the p < 0.05 level; HR = hazard ratio; CI = confidence interval; BMI = body mass index
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Table 3. Univariate and Multivariate Cox Proportional-Hazards Regression Analysis of the Trastuzumab Cohort
Characteristics
Anthracycline Dose
0 mg/m2
≤ 240 mg/m2
> 240 mg/m2
Radiotherapy
None
Left-Sided Only
Right-Sided Only
Age
≤ 65
> 65
BMI
Normal
Overweight
Obese
Hypertension
Diabetes
Dyslipidemia
Smoking History
Family History of Cardiac
Disease
Liver Disease

Unadjusted HR

(95% CI)

p-value

Adjusted HR

(95% CI)

p-value

Reference
1.03
2.24

--(0.60, 1.77)
(0.76, 6.55)

0.92
0.14

Reference
1.29
2.49

--(0.68, 2.46)
(0.59, 10.5)

0.44
0.21

Reference
0.27
0.49

--(0.13, 0.56)
(0.27, 0.91)

<0.001*
<0.001*

Reference
0.23
0.31

--(0.10, 0.52)
(0.15, 0.64)

<0.001*
0.0017*

Reference
3.97

--(1.99, 7.91)

<0.001*

Reference
2.31

--(0.78, 6.80)

0.13

Reference
0.84
0.95
1.12
0.59
2.03
1.69
0.79

--(0.46, 1.54)
(0.50, 1.82)
(0.64, 1.98)
(0.19, 1.89)
(1.17, 3.52)
(0.93, 3.10)
(0.47, 1.33)

0.57
0.88
0.68
0.38
0.011*
0.087
0.37

Reference
0.61
0.85
1.35
0.31
3.66
3.01
0.85

--(0.29, 1.28)
(0.35, 2.05)
(0.55, 3.36)
(0.07, 1.48)
(1.80, 7.42)
(1.42, 6.39)
(0.44, 1.62)

0.19
0.71
0.51
0.14
<0.001*
0.0040*
0.62

1.49

(0.59, 3.73)

0.40

2.07

(0.63, 6.73)

0.23

* Statistically significant at the p < 0.05 level; HR = hazard ratio; CI = confidence interval; BMI = body mass index
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Table 4. Baseline Imaging Parameters: Descriptive Summary of Anthracycline Cohort

Characteristic
Peak Filling Rate (PFR) (EDV/sec)
Normal (≥ 2.5)
Abnormal (< 2.5)
Left Ventricular End-Diastolic Volume
(LV EDV) (ml)
Normal (< 140)
Abnormal (≥ 140)
Left ventricular ejection fraction
(LVEF) (%)
Normal (≥ 50)
Abnormal (< 50)

All Breast
Cancer Patients
Receiving
Anthracycline
n = 496

Anthracycline Bevacizumab Trastuzumab

Anthracycline
+
Bevacizumab

Anthracycline
+
Trastuzumab

p-value

n = 389

n = 30

n = 76

427 (86.26)
68 (13.74)

336 (86.60)
52 (13.40)

27 (90.00)
3 (10.00)

64 (84.21)
12 (15.79)

0.75

414 (83.47)
82 (16.53)

324 (83.29)
65 (16.71)

27 (90.00)
3 (10.00)

62 (81.58)
14 (18.42)

0.62

491 (98.99)
5 (1.01)

386 (99.23)
3 (0.77)

30 (100.00)
0 (0.00)

75 (98.68)
1 (1.32)

0.62

Note: Data are n (%) of persons for whom data are available. Percentages may not sum to one hundred due to rounding.
* Statistically significant at the p < 0.05 level
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Table 5. Baseline Imaging Parameters: Univariate and Multivariate Cox Proportional-Hazards Regression Analysis of the
Anthracycline Cohort
Baseline Imaging Parameter
Peak Filling Rate (PFR) (EDV/sec)
Normal (≥ 2.5)
Abnormal (< 2.5)
Left Ventricular End-Diastolic Volume (LV
EDV) (ml)
Normal (< 140)
Abnormal (≥ 140)

Unadjusted HR

(95% CI)

p-value Adjusted HR

(95% CI)

p-value

Reference
0.78

--(0.37, 1.64) 0.51

Reference
0.74

--(0.29, 1.90) 0.53

Reference
1.80

--(1.05, 3.08) 0.032*

Reference
1.28

--(0.63, 2.61) 0.50

* Statistically significant at the p < 0.05 level
HR = hazard ratio; CI = confidence interval
Adjusted for cumulative anthracycline dose, additional treatment, chest radiotherapy, age, BMI, smoking history, family history of
cardiac disease, and comorbidities (hypertension, diabetes, dyslipidemia, and liver disease) in a multivariate Cox proportional-hazards
model
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